All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @taylormaemcd on TikTok · 28s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @taylormaemcd's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I'll see you in the next one.

@taylormaemcd's injection site advice, fact-checked

Taylor Mae • Wellness ✨

TikTok creator

127.4K viewsWatch on TikTok →

Quick answer

GLP-1 receptor agonists like semaglutide and tirzepatide are injected subcutaneously in the abdomen, thigh, or upper arm with equivalent absorption rates. The STEP and SURMOUNT trials used rotation between these sites and showed 15-20% average weight loss over 68-72 weeks.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion
Start provider reviewBrowse video library

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @taylormaemcd's injection site advice, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialSemaglutide evidence2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.

PubMed

Randomized trialSemaglutide evidence2021

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance

Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.

PubMed

Randomized trialTirzepatide evidence2022

Tirzepatide Once Weekly for the Treatment of Obesity

Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.

PubMed

Randomized trialTirzepatide evidence2024

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction

Used for continuation, stopping, and maintenance questions after initial weight loss.

PubMed

Video claim decision path

Turn the claim into a safer next question

Direct answer

@taylormaemcd's injection site advice, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Start the provider review

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Helpful context before the funnel

Review method

See how FormBlends checks viral health claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@taylormaemcd's injection site advice, fact-checked" from Taylor Mae • Wellness ✨. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide and tirzepatide are injected subcutaneously in the abdomen, thigh, or upper arm with equivalent absorption rates.

The reason this review is not generic is the source wording and the canonical claim label "glp1 back to above the belly button my 1 place in my bio t." In this clip, the useful excerpt is: "I'll see you in the next one." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The STEP 1 trial achieved 14.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide and tirzepatide are injected subcutaneously in the abdomen, thigh, or upper arm with equivalent absorption rates.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide and tirzepatide are injected subcutaneously in the abdomen, thigh, or upper arm with equivalent absorption rates. The STEP and SURMOUNT trials used rotation between these sites and showed 15-20% average weight loss over 68-72 weeks.
  • Clinical trials found no meaningful differences between FDA-approved injection sites (abdomen, thigh, upper arm)
  • The STEP 1 trial achieved 14.9% weight loss using multiple injection sites, not one preferred location

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Clinical trials found no meaningful differences between FDA-approved injection sites (abdomen, thigh, upper arm)
  • The STEP 1 trial achieved 14.9% weight loss using multiple injection sites, not one preferred location
  • Site rotation prevents lipodystrophy and tissue damage more effectively than using one "favorite" spot
  • Sponsored injection advice from influencers shouldn't replace guidance from prescribing healthcare providers
  • FTC guidelines require clear disclosure when health advice comes with financial partnerships
  • Telehealth platforms can legitimately prescribe GLP-1s but proper injection training should come from medical professionals

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this video actually claim?

TikTok creator @taylormaemcd tells her 127K viewers that injecting "above the belly button" is her "#1 place" for GLP-1 medications. She's promoting her partnership with Amble Health while sharing injection site preferences.

The video doesn't make specific medical claims about why this location is superior. It's more of a personal recommendation wrapped in wellness influencer marketing speak.

Does injection location actually matter for GLP-1s?

Yes, but probably not how you'd think. The SUSTAIN trials for semaglutide tested subcutaneous injections in the abdomen, thigh, and upper arm without finding meaningful differences in drug absorption or efficacy.

What matters more is rotating injection sites to prevent lipodystrophy (fatty tissue changes). The STEP trials, which showed 14.9% weight loss with 2.4mg semaglutide, used multiple injection sites throughout the studies.

Taylor's preference for above the belly button falls within FDA-approved abdominal injection areas. But calling it the "#1 place" oversells what the data actually shows.

What about the Amble Health partnership?

This is where things get murky. Taylor's promoting a telehealth platform while giving injection advice, which blurs the line between personal experience and sponsored content.

The FTC requires clear disclosure when health advice comes with financial incentives. While she includes #ambleptnr (presumably "Amble partner"), it's buried among 13 hashtags.

Telehealth platforms like Amble can provide legitimate GLP-1 prescriptions, but injection technique should come from your prescribing provider, not sponsored content.

What should you actually know about injection sites?

Stick to the basics that work. Novo Nordisk's prescribing information for Wegovy lists abdomen, thigh, and upper arm as equally effective sites.

Rotate locations within each area to prevent tissue damage. The clinical trials that proved these medications work used systematic rotation, not one "favorite" spot.

Your healthcare provider should demonstrate proper injection technique during your first visit. Don't rely on TikTok for medical procedures, even seemingly simple ones.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Taylor Mae • Wellness ✨ · TikTok creator

127.4K views on this video

back to above the belly button! my #1 place ✨ 🔗 in my bio to start your journey! #glp #glp1forweightloss #glp1medication #glp1girlies #glp1forpcos #pcos #taylormaemcd #glp1community #glp1journey #amb

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about clinical trials found no meaningful differences between fda-approved injection sites?

Clinical trials found no meaningful differences between FDA-approved injection sites (abdomen, thigh, upper arm)

What does the video say about the step 1 trial achieved 14.9% weight loss using multiple?

The STEP 1 trial achieved 14.9% weight loss using multiple injection sites, not one preferred location

What does the video say about site rotation prevents lipodystrophy?

Site rotation prevents lipodystrophy and tissue damage more effectively than using one "favorite" spot

What does the video say about sponsored injection advice from influencers shouldn't replace guidance from prescribing?

Sponsored injection advice from influencers shouldn't replace guidance from prescribing healthcare providers

What does the video say about ftc guidelines require clear disclosure?

FTC guidelines require clear disclosure when health advice comes with financial partnerships

What does the video say about telehealth platforms can legitimately prescribe glp-1s?

Telehealth platforms can legitimately prescribe GLP-1s but proper injection training should come from medical professionals

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Taylor Mae • Wellness ✨, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.